02157 LEPU BIO-B
- 6.150
- +0.640+11.62%
LEPU BIO-B News
Lepu Biopharma Co., Ltd.'s (HKG:2157) 58% Share Price Surge Not Quite Adding Up
Lepu Biopharma Co., Ltd. (HKG:2157) shareholders have had their patience rewarded with a 58% share price jump in the last month. But the gains over the last month weren't enough to make shareholder
樂普生物-B：2023年度報告
Changes in Hong Kong stocks | Lepu Bio-B (02157) rose more than 7% to complete clinical trial of a drug to treat advanced solid tumors
Lepu Bio-B (02157) rose more than 7%, rising by about 45% during the month. As of press release, it rose 5.95% to HK$4.63, with a turnover of HK$14.9943 million.
Is Lepu Biopharma (HKG:2157) A Risky Investment?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company is, we always like to look at its use of debt, since debt overload can lead to rui
Lepu Bio-B (02157.HK): Recent developments in the licensing agreement with ASTRAZENECA for CMG901
Lepu Bio-B (02157.HK) announced the latest status of the exclusive global license agreement between KYM Biosciences Inc. (“KYM”, a joint venture formed by the Company and Connoya Biomedical Technology Co., Ltd. (“Connoya”) and AstraZeneca AB (“AstraZeneca”, a global pharmaceutical company) for the development and commercialization of CMG901 (a drug candidate developed jointly by the company and Connoya through KYM).
Changes in Hong Kong stocks | Lepu Bio-B (02157) rose more than 5%, commercialization achieved a breakthrough, and revenue soared 1347% last year
Lepu Bio-B (02157) rose more than 5%. As of press release, it rose 5.95% to HK$3.56, with a turnover of HK$3.336,800.
Looking at the increase in value of Lepu Bio-B (2157.HK) from an annual report that “combines speed and quality”
In 2023, due to the combined effects of macroeconomic factors such as global economic fluctuations, capital market performance was not ideal. In particular, the innovative drug sector of Hong Kong stocks continued to fluctuate and adjust. The market further released pessimistic values, and sector valuations also fell to a historically low range for a while. At the same time, the domestic healthcare industry's financing environment has also been significantly affected. According to the Sino-Thai International Research Report, the total financing of the domestic healthcare industry fell 30.1% year on year to 10.9 billion US dollars in 2023, equivalent to about 1/3 of 2021 and falling back to around 2017. Pan Tianqi of the League of Nations Foundation believes that the present is just what is expected
Breakthrough in business development and commercialization, Lepu Bio-B (02157)'s revenue in 2023 soared 1347% to 225 million yuan
Lepu Bio-B (02157) disclosed the 2023 annual results announcement. The group achieved revenue of 2.25 during the reporting period...
LEPU BIO-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Lepu Bio-B (02157.HK) held a board meeting on March 27 to consider and approve annual results
Glonghui March 15 | Lepu Bio-B (02157.HK) announced that the board of directors meeting will be held on March 27, 2024 (Wednesday) to consider and approve (among other things) the annual results and announcements of the company and its subsidiaries for the year ended 31 December 2023, consider recommending payment of a final dividend (if any), and deal with other matters.
LEPU BIO-B: NOTICE OF BOARD MEETING
Changes in Hong Kong stocks | Lepu Bio-B (02157) rose more than 13% at the end of the session, and a candidate drug candidate for pancreatic cancer was granted fast track status by the US
Lepu Bio-B (02157) rose more than 13% at the end of the session. As of press release, it was up 9.09% to HK$3.6, with a turnover of HK$10.4921 million.
Lepu Biopharma's Pancreatic Cancer Drug Gets US FDA Fast-Track Designation
The US Food and Drug Administration granted Lepu Biopharma (HKG:2157) fast-track status for its MRG004A pancreatic cancer treatment, according to a Monday filing with the Hong Kong bourse. The designa
Lepu Bio-B (02157): MRG004A for the treatment of pancreatic cancer was granted fast-track status by the FDA
Lepu Bio-B (02157) announced that the company's drug candidate MRG004A (a novel targeted tissue factor...
Selling Lepu Biopharma Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders
Lepu Biopharma Co., Ltd.'s (HKG:2157) stock price has dropped 31% in the previous week, but insiders who sold CN¥18m in stock over the past year have had less luck. Insiders would probably have been
Lepu Bio-B plans to re-elect Pu Zhongjie as the executive director of the second board of directors
Lepu Bio-B (02157) announced that since the term of the first board of directors expired on December 9, 2023, it was proposed to re-elect Pu Zhongjie and Sui Ziye as executive directors of the second board of directors; re-elect Pu Jue and Yang Hongbing as non-executive directors of the second board of directors; and re-elect Zhou Demin, Yang Haifeng, and Hua Fengmao as independent non-executive directors of the second board of directors. Hu Chaohong decided to retire and no longer hold the position of co-general manager of the company, and will no longer serve as an executive director after the second board election. In addition, Lin Xianghong will be a director for the second term
Lepu Bio-B (02157) plans to re-elect Pu Zhongjie as the executive director of the second board of directors
Zhitong Finance App News, Lepu Bio-B (02157) issued an announcement. Since the term of the first board of directors expired on December 9, 2023, it was proposed to re-elect Pu Zhongjie and Sui Ziye as executive directors of the second board of directors; re-election of Pu Jue and Yang Hongbing as non-executive directors of the second board of directors; and re-election of Zhou Demin, Yang Haifeng, and Hua Fengmao as independent non-executive directors of the second board of directors. Hu Chaohong decided to retire and no longer hold the position of co-general manager of the company, and will no longer serve as an executive director after the second board election. Furthermore, Lin Xiang
Hang Seng Healthcare Index rose 1.16%; Hanson Pharmaceuticals (03692) rose 6.61%
Jinwu Financial News | Hang Seng Healthcare Index rose 1.16%. Among the constituent stocks, Metz Health (02415) rose 8.1%, Hanson Pharmaceuticals (03692) rose 6.61%, Lepu Biotech (02157) rose 5.28%, minimally invasive robotics (02252) rose 3.98%, and Ping An Good Doctor (01833) rose 3.31%. The CDB Securities Research Report pointed out that although the short-term pharmaceutical industry has been adjusted due to the overall market situation, the industry has ushered in positive factors and changes in terms of policy, performance, valuation level, and position level. Continue to focus on the main line of innovation that has ushered in positive changes
Galaxy Securities: Entering a New Era of Targeted Chemotherapy, Focusing on the High Quality Circuit ADC in the Field of Innovative Drugs
According to Galaxy Securities, ADC is a high-quality circuit in the field of innovative drugs. Its targets with high technical barriers and strong platform expandability, leading pipeline progress, and remarkable clinical efficacy are worthy of continuous investment and tracking.
Lepu Bio-B (02157.HK): MRG003 is used to treat recurrence/metastatic nasopharyngeal cancer (R/M NPC) who completed key registration phase IIb clinical trials
Gelonghui, December 29 | Lepu Bio-B (02157.HK) announced that the company's drug candidate MRG003 (an epidermal growth factor receptor (“EGFR”) antibody drug conjugate (“ADC”) drug candidate and the company's core product) has recently successfully completed the enrollment of all subjects in key registered phase IIb clinical trials to treat recurrent or metastatic nasopharyngeal cancer (“R/M NPC”). This trial is a randomized, open, multi-center key registration phase IIb clinical study. Enrollment of subjects began in April 2023. As of the date of this announcement, 1
Analysis
Price Target
No Data
